|
The National Institutes of Health (NIH) is the leading federal agency supporting research related to improving the nation's health. The scientists and clinicians whom it has helped train and support have consistently been at the forefront of research discoveries that have advanced fundamental knowledge of human biology and of better ways to treat or prevent disease and promote good health. Over the past 50 years, NIH as an institution has played a major role in the explosion of knowledge that has amounted to a revolution in biology. NIH's success has earned it steadily increasing budgets even when the overall federal budget has been tight, as it has been in recent years. Although the NIH budget for the current fiscal year (1998) is more than $13 billion and both the administration and the U.S. Congress have promised a substantial increase for 1999, it will never be large enough to meet every need or fund every promising lead. Choices must be made and priorities must be set. Concerns about priority setting in the allocation of NIH research funding come from several sources. First, some members of Congress believe that there should be more of a correlation between the allocation of funding by disease and the distribution of disease burdens and costs in the population. Second, more and more disease-specific interest groups have begun campaigning for increases in NIH funding related to particular diseases. Additionally, many of these groups do not feel that NIH listens or responds to their inputs. Finally, the leadership of the health committees in Congress has become increasingly uncomfortable with intervening in research priority setting at NIH, for example, by mandating specific funding set-asides, new programs or institutions focused on specific diseases, or the use of particular research mechanisms or by trying to push research advances in specific areas in other ways. For these reasons, this committee has been asked to evaluate the processes for setting priorities at NIH, particularly NIH's mechanisms for obtaining public input and the role of Congress in directing the allocation of funding among areas of research. In setting priorities, NIH must also adapt to a changing policy environment. Despite having a growing budget, scientific research opportunities have grown even more rapidly, as has awareness of health problems as the population ages and as globalization exposes the U.S. population to emerging or reemerging infectious diseases.
To meet the expectations
of the American people and fulfill the agency's mission, NIH's
leaders must pursue many objectives. Two of the most important
are (1) to identify the public's health needs, reducing the burdens
of illness by developing better methods of prevention, diagnosis,
treatment, and rehabilitation, and (2) to extend the basic knowledge
base to lead to even better methods in the future. These two objectives
are complementary and must be pursued with equal intensities if
NIH is going to be successful. A third important objective is
to communicate to the public and health providers the current
state of scientific knowledge and the implications of research
advances for improving the nation's health. Box 1 describes some
of NIH's constituencies.
Identifying the burden of
illness, however, is not a straightforward task. As indicated
in the NIH booklet "Setting Research Priorities at the National
Institutes of Health" (National Institutes of Health, 1997b)
(referred to hereafter as Setting Research Priorities), there
are many ways to measure the burden of disease because the problem
can be analyzed and interpreted from many different perspectives.
These are all relevant because the concept of the burden of disease
is very broad.
Assessing the burden of disease takes into account the fact that the benefits of past research have not reached everyone, indicated by significant differentials in disease rates and outcomes among different socioeconomic and ethnic groups. Also, about half the nation's health care costs result from unhealthy behaviors and environments, which pose major research challenges. In addition, state-of-the-art screening, diagnostic procedures, and treatments are not reaching everyone, resulting in unnecessary burdens of undetected or poorly treated diseases, and patient and provider knowledge could be improved through education. All of these factors must be weighed and balanced in the priority-setting process. The committee assessed NIH's priority-setting process in light of the agency's mission and objectives and the changing policy environment. Are the criteria adequate? Is the process for implementing them working? Given the objective of responding to health needs as well as scientific opportunity, in conjunction with the expansion of organized disease-specific interest groups, are the mechanisms for public input adequate, or can they be changed to increase the complementarity between NIH's goals of responding to health needs and scientific opportunity? Can Congress, the holder of the public purse strings, be assured that NIH has a rigorous process for priority setting in which the full range of considerations is taken into account in planning programs and allocating funding?
The committee concludes that
NIH's system for setting priorities has generally served NIH and
the nation well in supporting research to improve human health,
but some changes would strengthen it, especially in mechanisms
for exchanging information and concerns with interested individuals
and groups. NIH should more fully engage the public-that is, the
public should have greater opportunity to learn about and provide
input into the process by which NIH sets its research priorities-in
a process that is led by the NIH director, guided by reasonable
criteria, and well informed by robust analyses of health statistics.
The process should be open and understandable, include multiyear
strategic planning, and give appropriate consideration to the
competing needs of scientific opportunity and disease burden.
Effective implementation of such a process would improve public
access to the process and limit the need for congressional directives.
The committee reviewed the
major criteria that NIH uses in its overall priority setting.
These criteria were explicitly laid out in Setting Research Priorities,
and the committee concluded that they are generally reasonable
and useful both for allocating research resources and for enabling
organized interest groups, members of Congress, and members of
the public to understand and evaluate NIH's program. The criteria
are The committee wants to be sure, however, that the conceptualization of the first criterion, public health needs, be broadened beyond the medical model implied in the discussion of the criterion in the booklet to include the preservation and maintenance of health and function.
To enhance the legitimacy of and support for its priority-setting and resource allocation processes, NIH should work to increase the level of understanding of its criteria by the general public and of how they are implemented and should engage in regular evaluations of how the criteria are used and of their impacts. The Setting Research Priorities booklet and other documents are not as effective at gaining public understanding as they could be, for example, in informing citizens who are concerned about health and particular diseases about how they can become involved (an issue addressed more fully below in the section Mechanisms for Public Input).
The committee found that some of the information needed for priority setting, especially data on disease burden and costs, is obtained rather informally and concluded that NIH should be more systematic in obtaining and analyzing such data. It should be kept in mind, however, that there is no simple metric for the use of these data, and the relationship between such data and allocations of research funding will not be simple because health problems are not equally ripe for research advances.
Individuals and groups concerned about specific health problems or health research often use NIH-generated data on spending by specific disease or area of research to assess the overall research portfolio. The data are not of the quality that they could be, however, and NIH should work to improve the data and to better explain the data to the public. Calculations of spending by disease should include not only all research directly related to the disease but also research projects on fundamental areas indirectly related to that disease. Users of the data should know that such calculations reflect the best estimates of all NIH spending in particular areas and that fundamental science is essential to understanding the etiology and progression of disease.
NIH should also collect and
analyze data on health research spending by others, such as other
federal agencies, industry, nonprofit health organizations that
fund research, foundations, or other countries. This should help
identify gaps, overlaps, and opportunities for joint efforts and
ensure that NIH invests wisely in areas and approaches that no
one else is funding, provides the appropriate coordination, and
supports the training of personnel and the other infrastructure
needed in the national research enterprise.
Priority setting is decentralized at NIH, which is appropriate for a research organization in which those closest to a problem are in the best position to decide on approaches and in which expertise is highly specialized. The priority-setting processes also vary from institute to institute and from area to area within institutes. Some such variation is appropriate, because the institutes vary in their missions, histories, leadership, sizes, and complexities. The committee did find that some institutes and programs have priority-setting processes that incorporate a broader range of inputs and views, including those of nonresearchers and nonclinicians. More recently, NIH has been making decisions on priorities and funding allocations that are more centralized than in the past; that is, NIH is looking across traditionally independent institutes and centers and focusing on certain crosscutting needs and opportunities where joint or unified action is desirable. This trend stems from the growing realization that common biological processes underlie diseases that were previously seen as different or that important diseases and other health problems are more complex than was previously thought, affect more organs and processes than was previously realized, and happen to be addressed in more than one institute.
The committee concluded that
the Office of the Director of NIH needs an increased capacity
to analyze such crosscutting needs and opportunities and to interact
with the public (the latter process-related issue is addressed
separately below). Improvement requires a more central role for
the NIH director and more uniformity in the data and analyses
presented to the Office of the Director.
In any organization, change
toward centralization raises concerns about accountability. As
the authority of the director is strengthened, greater accountability
of the director's office could be achieved through a strengthened
Advisory Committee to the Director, one that is more actively
engaged in the NIH priority-setting process and that has a broader
base of membership, especially among its public members.
Although a major criterion in research priority setting is public health needs, the committee found that NIH's interaction with various kinds of publics is generally weak compared with NIH's interaction with the research community. This is especially true for the Office of the Director of NIH, which does not have adequate channels through which members of the public can express their concerns to NIH or through which they can receive information about the broad scope of effort being made in the fields with which they are concerned.
This structural weakness
has important complications: first, because patient advocacy groups
have become better organized and more proactive on behalf of their
interests and have greatly increased their appeals to Congress
to intervene to adjust NIH research priorities; second, because
congressional leaders have expressed a strong desire to avoid
mandates and earmarks in favor of particular diseases and to let
NIH set research priorities; and third, because the NIH director
has increased his role in priority setting (partly by exercising
additional authorities granted to him by Congress). This confluence
of events highlights the need for improved communication between
the public and NIH.
NIH should engage the public
to a greater extent in informing the process by which NIH sets
its research priorities. The following three recommendations are
intended to provide the public with more opportunities to present
their views regarding research needs and to receive information
about research and the priority-setting process at NIH.
The Offices of Public Liaison are meant to serve several purposes: (1) they provide an easily identifiable point of contact for individuals and groups who have an interest or concern; (2) they are a place where members of Congress can refer constituents who want to obtain information or to raise concerns; and (3) they conduct an active program of outreach to and interaction with constituency groups. The NIH director's Office of Public Liaison will oversee and coordinate the institutes' Offices of Public Liaison, serve as a point of contact for individuals or groups who are dealing with crosscutting issues or who do not have a specific institute to contact, and staff the Director's Council of Public Representatives (discussed below).
The Director's Council of Public Representativesan advisory group made up of citizens who are either patients, family members of patients, or advocates for patientsserves to elevate public input into the priority-setting process to the highest level of NIH in a systematic and periodic manner. Importantly, the Council will not set priorities regarding the NIH budget or its research programs. That is, it is not intended to serve as a forum for advocacy groups to lobby the NIH director for research dollars. Rather, it is intended to serve as a mechanism for NIH to receive valuable and thoughtful perspectives on its research programs from those who are in some way affected by disease and disability and who are therefore advocates for a healthy NIH and for NIH to provide information about its research and priority-setting process as part of a two-way exchange of information.
Together with the Offices
of Public Liaison, the Director's Council of Public Representatives
would permit continual interaction between NIH and the public.
The Council would allow the NIH director to hear periodically
from representatives of a spectrum of interest groups; the Offices
of Public Liaison, which would be staff offices that function
on a daily basis, unlike the Council, would provide information
to and receive input from interested groups and congressional
offices and would staff the Council in the Office of the Director.
Figure 1 shows the proposed placement of the Offices of Public
Liaison and the Director's Council of Public Representatives within
the current organization at NIH.
NIH has long-standing mechanisms by which to include public or lay members on top-level advisory bodies. In the institutes, these councils provide advice and guidance on their research programs and funding decisions by providing the second layer of review (the first being peer review through the study sections). Thus, public representatives play a role in the priority-setting process and provide advice on funding decisions. NIH also reserves slots for public members on the Advisory Committee to the Director. It does not appear, however, that advocates for patients or special populations are regularly considered for these advisory committee memberships, despite numerous examples of cases in which such arrangements have been constructive and positive. Not using this mechanism to receive public input is a missed opportunity and has resulted in the perception of some groups that NIH does not encourage public input at the highest levels of its advisory processes. These recommendations are not intended to replace the existing criteria for priority setting. They are intended to enhance and reinforce existing NIH mechanisms through which the voices of the public can be heard in a constructive and open manner. The committee believes that public input, which has been important in sustaining the growth and stature of NIH, is an important component of the priority-setting process and, if used wisely by NIH when setting research priorities, will make for a stronger and more responsive NIH. It also believes that although implementation of these recommendations will not supersede or remove the potential for appeals to Congress, their enactment will reduce the need for such appeals.
The new organizational mechanisms
proposed to improve public input have the potential to increase,
in the short term, organizational costs and complexity. In the
long run, however, the committee believes that the contribution
made by these offices and the Council will prove to be cost-effective
in terms of carrying out NIH's mission to improve health through
research and will contribute to overall goodwill on the part of
the public and Congress toward NIH.
Congress has always taken a special interest in NIH and has usually provided for larger budgets than administrations request. Congress has also often directed NIH in fairly specific ways, requiring the establishment of research programs, setting aside specific amounts of funding for research on designated problems, mandating the creation of research centers, institutes, or other specific mechanisms, and so forth. Congress has the authority and the responsibility to intervene if it thinks that NIH is neglecting an opportunity or is not responsive to a need. Members of Congress recognize that it would be better for NIH to make the detailed decisions on how to approach problems.
The committee believes that
if NIH revises its priority-setting system in the ways recommended
above, Congress will be more likely to grant NIH (which, it is
hoped, will be informed by stronger public input) the primary
role in setting its research priorities. The text of the report
includes some guidelines first offered by an Institute of Medicine
committee in 1984 for Congress to use in deciding whether to mandate
major organizational changes.
If NIH is to have more autonomy
in organizing and managing its research programs, it is incumbent
on the agency to engage in periodic reviews of its organizational
structure and planning and budgeting systems and to explain the
results to Congress and the public.
The committee questions whether
NIH, especially the Office of the Director, has adequate resources
to operate an effective priority-setting system. Providing the
Office of the Director of NIH with adequate resources for analysis
and interface with the public would make research priority setting
more effective.
|